Analysts’ Weekly Ratings Changes for Aardvark Therapeutics (AARD)

A number of firms have modified their ratings and price targets on shares of Aardvark Therapeutics (NASDAQ: AARD) recently:

• 3/10/2025 – Aardvark Therapeutics is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $29.00 price target on the stock.
• 3/10/2025 – Aardvark Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $50.00 price target on the stock.
• 3/10/2025 – Aardvark Therapeutics is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $21.00 price target on the stock.
• 3/10/2025 – Aardvark Therapeutics is now covered by analysts at Bank of America Co.. They set a “buy” rating and a $22.00 price target on the stock.

Aardvark Therapeutics Stock Performance

Shares of Aardvark Therapeutics stock opened at $9.26 on Tuesday. Aardvark Therapeutics, Inc. has a 12-month low of $9.21 and a 12-month high of $19.58.

Insider Activity at Aardvark Therapeutics

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Tien-Li Lee purchased 16,542 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. The trade was a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.